tradingkey.logo

J&J Anticipate Second Half Operational Sales Growth Higher Than First Half - Presentation

ReutersJul 16, 2025 11:43 AM

- Johnson & Johnson JNJ.N:

  • J&J: ANTICIPATE SECOND HALF OPERATIONAL SALES GROWTH HIGHER THAN FIRST HALF - PRESENTATION

  • J&J: IN INNOVATIVE MEDICINE, NEGATIVE IMPACT OF PART D RE-DESIGN, AS A PERCENT TO SALES, WILL BE CONSISTENTLY APPLIED THROUGHOUT YEAR

  • J&J: PRODUCTS NEGATIVELY IMPACTED BY PART D RE-DESIGN INCLUDE STELARA, INVEGA LONG ACTING INJECTABLES, ERLEADA, OPSUMIT, UPTRAVI, TREMFYA & IMBRUVICA

Source text: [ID:]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI